These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11066021)

  • 1. An investigation of the solubility of various compounds in the hydrofluoroalkane propellants and possible model liquid propellants.
    Dickinson PA; Seville PC; McHale H; Perkins NC; Taylor G
    J Aerosol Med; 2000; 13(3):179-86. PubMed ID: 11066021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solubility of solid solutes in HFA-134a with a correlation to physico-chemical properties.
    Hoye JA; Gupta A; Myrdal PB
    J Pharm Sci; 2008 Jan; 97(1):198-208. PubMed ID: 17828733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Issues surrounding MDI formulation development with non-CFC propellants.
    Kontny MJ; Destefano G; Jager PD; McNamara DP; Turi JS; Van Campen L
    J Aerosol Med; 1991; 4(3):181-7. PubMed ID: 10147677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of water on the solubility of two steroid drugs in hydrofluoroalkane (HFA) propellants.
    Williams RO; Hu C
    Drug Dev Ind Pharm; 2001 Jan; 27(1):71-9. PubMed ID: 11247538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reverse water-in-fluorocarbon emulsions for use in pressurized metered-dose inhalers containing hydrofluoroalkane propellants.
    Butz N; Porté C; Courrier H; Krafft MP; Vandamme TF
    Int J Pharm; 2002 May; 238(1-2):257-69. PubMed ID: 11996829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prodrug to probe solution HFA pMDI formulation and pulmonary esterase activity.
    Seville PC; Simons C; Taylor G; Dickinson PA
    Int J Pharm; 2000 Feb; 195(1-2):13-6. PubMed ID: 10675676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding solvation in hydrofluoroalkanes: ab initio calculations and chemical force microscopy.
    Wu L; Peguin RP; da Rocha SR
    J Phys Chem B; 2007 Jul; 111(28):8096-104. PubMed ID: 17580855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement and correlation of solute solubility in HFA-134a/ethanol systems.
    Hoye JA; Myrdal PB
    Int J Pharm; 2008 Oct; 362(1-2):184-8. PubMed ID: 18647644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of reference ultrasound parameters for model and hydrofluoroalkane propellants using high-resolution ultrasonic spectroscopy.
    Hoe S; Young PM; Rogueda P; Traini D
    AAPS PharmSciTech; 2008; 9(2):605-11. PubMed ID: 18459053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surfactant solubility and aggregate orientation in hydrofluoroalkanes.
    Ridder KB; Davies-Cutting CJ; Kellaway IW
    Int J Pharm; 2005 May; 295(1-2):57-65. PubMed ID: 15847991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ester group: how hydrofluoroalkane-philic is it?
    Peguin RP; Wu L; da Rocha SR
    Langmuir; 2007 Jul; 23(16):8291-4. PubMed ID: 17602576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of two methods to determine the solubility of compounds in aerosol propellants.
    Gupta A; Myrdal PB
    Int J Pharm; 2005 Mar; 292(1-2):201-9. PubMed ID: 15725567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel method for the determination of solubility in aerosol propellants.
    Gupta A; Myrdal PB
    J Pharm Sci; 2004 Oct; 93(10):2411-9. PubMed ID: 15349951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moisture uptake and its influence on pressurized metered-dose inhalers.
    Williams RO; Hu C
    Pharm Dev Technol; 2000; 5(2):153-62. PubMed ID: 10810745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D; Vicaut E; Lefrançois G;
    Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of solubility of steroids in hydrofluoroalkane propellants.
    Williams RO; Rogers TL; Liu J
    Drug Dev Ind Pharm; 1999 Dec; 25(12):1227-34. PubMed ID: 10612017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of expansion chamber geometry on atomization and spray dispersion characters of a flashing mixture containing inerts. Part I. Numerical predictions and dual laser measurements.
    Ju D; Shrimpton J; Bowdrey M; Hearn A
    Int J Pharm; 2012 Aug; 432(1-2):23-31. PubMed ID: 22575753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surfactant dissolution and water solubilization in chlorine-free liquified gas propellants.
    Blondino FE; Byron PR
    Drug Dev Ind Pharm; 1998 Oct; 24(10):935-45. PubMed ID: 9876548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metered dose inhalers in the transition to low GWP propellants: what we know and what is missing to make it happen.
    Buttini F; Glieca S; Sonvico F; Lewis DA
    Expert Opin Drug Deliv; 2023; 20(8):1131-1143. PubMed ID: 37767756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-surfactant-propellant interactions in HFA-formulations.
    Vervaet C; Byron PR
    Int J Pharm; 1999 Sep; 186(1):13-30. PubMed ID: 10469920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.